MedTrace Logo

Asprosin in Breast Cancer

NCT06592560 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2024-09-19

No results posted yet for this study

Summary

To evaluate the clinical utility of Asprosin measurement in breast cancer patients in comparison with healthy controls and patients with benign breast lesions.

To compare between Asprosin and the routine markers (CEA, CA15-3) as biomarkers for breast cancer diagnosis

Conditions

Interventions

DEVICE

ELISA

Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).

Sponsors & Collaborators

  • Marina Hanna Thabet Ghobrial

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-31
Primary Completion
2025-09-30
Completion
2025-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06592560 on ClinicalTrials.gov